John A.  Roberts net worth and biography

John Roberts Biography and Net Worth

CEO of Vyant Bio
Mr. Jay Roberts has been the President and Chief Executive Officer of Vyant Bio, Inc. since 2018. Mr. Roberts had previously served as the Chief Operating Officer of Cancer Genetics. Prior to joining Cancer Genetics, Mr. Roberts served as the Chief Financial Officer for VirMedica, Inc., an innovative technology solutions company that provides an end-to-end platform that enables specialty-drug manufacturers and pharmacies to optimize product commercialization and management. Before VirMedica, Mr. Roberts was the Chief Financial and Administrative Officer for AdvantEdge Healthcare Solutions Inc., a global healthcare analytics and services organization. Prior to that, Mr. Roberts also served as the Chief Financial Officer and Treasurer for InfoLogix, Inc., a publicly-traded, healthcare-centric mobile software and solutions provider. He has also held CFO roles at leading public medical device and healthcare services firms including Clarient, Inc., a publicly-traded provider of diagnostic laboratory services, and Daou Systems, Inc., a publicly-traded healthcare IT software development and services firm. In addition, he has held key senior executive roles with MEDecision, Inc., HealthOnline, Inc., and the Center for Health Information. Mr. Roberts earned a Bachelor of Science and a master’s degree in Business Administration from the University of Maine. He is a member of the Fellows and a former member of the Board of Directors and Past Chair for the Drug Information Association, a global neutral forum enabling drug developers and regulators access to education and collaboration. Mr. Roberts also serves on the Board of Directors of Cohere-Med Inc., a clinical analytics company.

What is John A. Roberts' net worth?

The estimated net worth of John A. Roberts is at least $59,184.74 as of May 24th, 2021. Mr. Roberts owns 305,076 shares of Vyant Bio stock worth more than $59,185 as of November 22nd. This net worth estimate does not reflect any other investments that Mr. Roberts may own. Learn More about John A. Roberts' net worth.

How do I contact John A. Roberts?

The corporate mailing address for Mr. Roberts and other Vyant Bio executives is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. Vyant Bio can also be reached via phone at (201) 479-1357 and via email at [email protected]. Learn More on John A. Roberts' contact information.

Has John A. Roberts been buying or selling shares of Vyant Bio?

John A. Roberts has not been actively trading shares of Vyant Bio within the last three months. Most recently, on Wednesday, November 24th, John A. Roberts bought 5,000 shares of Vyant Bio stock. The stock was acquired at an average cost of $2.02 per share, with a total value of $10,100.00. Learn More on John A. Roberts' trading history.

Who are Vyant Bio's active insiders?

Vyant Bio's insider roster includes Marcus Boehm (Director), R. Fletcher (Director), Paul Hansen (Director), John Roberts (CEO), and Yung-Ping Yeh (Insider). Learn More on Vyant Bio's active insiders.

John A. Roberts Insider Trading History at Vyant Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/24/2021Buy5,000$2.02$10,100.00View SEC Filing Icon  
8/23/2021Buy10,406$2.41$25,078.46View SEC Filing Icon  
5/26/2021Buy7,041$3.55$24,995.55305,076View SEC Filing Icon  
5/24/2021Buy7,440$3.38$25,147.20305,076View SEC Filing Icon  
1/31/2019Buy185,436$0.23$42,650.28297,636View SEC Filing Icon  
1/14/2019Buy100,000$0.23$23,000.00112,200View SEC Filing Icon  
12/15/2017Buy12,200$2.00$24,400.0012,200View SEC Filing Icon  
See Full Table

John A. Roberts Buying and Selling Activity at Vyant Bio

This chart shows John A Roberts's buying and selling at Vyant Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vyant Bio Company Overview

Vyant Bio logo
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.
Read More

Today's Range

Now: $0.19
Low: $0.18
High: $0.20

50 Day Range

MA: $0.19
Low: $0.19
High: $0.19

2 Week Range

Now: $0.19
Low: $0.14
High: $1.58

Volume

19,100 shs

Average Volume

161,822 shs

Market Capitalization

$1.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73